Phio Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that CEO Robert Bitterman will present the company's INTASYL siRNA therapeutic platform and its lead candidate PH-762, aimed at treating skin cancers like cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The presentation, part of the Renmark Financial Virtual Non-Deal Roadshow on October 20, 2026, will include a live Q&A session. PH-762 is a potential non-surgical treatment that silences the PD-1 gene to enhance immune response against cancer cells. The company is preparing for the next phase of clinical development and regulatory discussions with the FDA, expected to progress in early 2027.
Phio Pharmaceuticals' upcoming presentation on its INTASYL siRNA therapeutic platform provides context for readers interested in biopharmaceutical innovation. For readers following the health sector, here is Pluang's market snapshot as of Oct 19, 2026 20:02 WIB: out of 150 priced US health stocks, 62 rose and 66 fell today. Among notable movers, AbCellera Biologics Inc (ABCL) and Arrowhead Pharmaceuticals Inc. (ARWR) both gained 1.27%, priced at USD 11.95 and USD 56.61 respectively, while Ginkgo Bioworks Holdings Inc (DNA) also rose 1.27% to USD 10.40. Typical hold times on Pluang vary widely, from 8 days for DNA to 41 days for ABCL.
Bill Gross, a serial entrepreneur behind over 175 companies, has launched Idealab.ai, a platform using AI to generate and share over 1.2 million business ideas based on real-world problems. The platform aims to lower barriers to entrepreneurship by h...
The Portnoy Law Firm has launched an investigation into Cardinal Infrastructure Group for possible securities fraud following the company's Q2 2026 financial report. Cardinal revealed a decline in its gross profit margin to 10.8%, down from 13.9% the...
AIOS Tech Inc. announced an agreement to acquire SmartCore Holdings Limited in an all-stock transaction valued at approximately $100 million. The deal will issue 33.3 million AIOS shares to SmartCore's sellers, who will hold about 80% of AIOS shares ...
XBiotech announced positive results from the Phase II TASKIN trial, where their antibody vilamakitug combined with standard chemotherapy improved 12-month overall survival to 61.3% in refractory metastatic colorectal cancer patients, surpassing the s...
Proof and Circle Internet Group demonstrated a new system where AI agents can prove the identity of the person they represent using Proof's x401 open identity protocol and pay merchants in USDC via Circle's x402 payment protocol. This innovation addr...
